| Officer | Age | In this role | Joined | 2024 pay | Source |
|---|---|---|---|---|---|
|
Charles Todd Fagan
Chief Financial Officer
Title from the Form 3 dated Aug 11, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Joshua Silverman
Also a director
Executive Chairman
Title from the Form 4 dated Jul 10, 2026
|
55 | Not stated | Not stated | Not reported | |
|
Yossef Ehrlichman
Chief Technology Officer
Title from the Form 3 dated Sep 14, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Mitchell Glass
Also a director
Chief Medical Officer
Title from the Form 4 dated Apr 13, 2026
|
73 | Not stated | Not stated | $182,333 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Reimbursement payment for expenses incurred meeting with potential strategic corporate partners on behalf of the Company
Purchase of 2,750 shares of Series F Preferred Stock and warrants for 40,651 shares of Common Stock in the February 2023 offering
Purchase of 5,000 shares of Series F Preferred Stock and warrants for 73,910 shares of Common Stock in the February 2023 offering
Purchase of 750 shares of Series F-1 Preferred Stock with long-term and short-term Series F-1 warrants in the May 2024 Series F-1 offering
Purchase of 1,400 shares of Series F-1 Preferred Stock with long-term and short-term Series F-1 warrants in the May 2024 Series F-1 offering
Purchase of 2,150 shares of Series F-1 Preferred Stock with long-term and short-term Series F-1 warrants in the May 2024 Series F-1 offering
Purchase of 500 shares of Series F-1 Preferred Stock with long-term and short-term Series F-1 warrants in the May 2024 Series F-1 offering
Purchase of 250 shares of Series F-1 Preferred Stock with long-term and short-term Series F-1 warrants in the May 2024 Series F-1 offering
Purchase of 7,000 shares of Series G Preferred Stock with long-term and short-term Series G warrants in the May 2024 Series G offering
Purchase of 750 shares of Series G Preferred Stock with long-term and short-term Series G warrants in the May 2024 Series G offering
Purchase of 1,000 shares of Series G Preferred Stock with long-term and short-term Series G warrants in the May 2024 Series G offering
Sale to Prevail of 283,019 shares of Common Stock at $2.12 per share under a Stock Purchase Agreement dated October 1, 2024
Loading...
